Currently, Bicara Therapeutics Inc [BCAX] is trading at $14.54, down -6.97%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCAX shares have gain 19.57% over the last week, with a monthly amount glided 10.99%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on April 17, 2025, when Wells Fargo initiated its Underweight rating and assigned the stock a price target of $8. Previously, Wedbush started tracking the stock with Outperform rating on February 06, 2025, and set its price target to $31. On December 06, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $42 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $48 on November 05, 2024. TD Cowen initiated its recommendation with a Buy. Stifel started tracking with a Buy rating for this stock on October 08, 2024, and assigned it a price target of $47. In a note dated October 08, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $35 on this stock.
This stock has fluctuated between a low of $8.91 and a high of $28.09 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $14.54 at the most recent close of the market. An investor can expect a potential return of 230.12% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.27 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.10 points at the first support level, and at 13.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.29, and for the 2nd resistance point, it is at 16.04.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bicara Therapeutics Inc [NASDAQ:BCAX] is 27.93. In addition, the Quick Ratio stands at 27.93 and the Cash Ratio stands at 27.22.
Transactions by insiders
Recent insider trading involved Meisner Lara, Chief Legal Officer, that happened on Mar 14 ’25 when 79146.0 shares were sold. Officer, LARA S. MEISNER completed a deal on Mar 14 ’25 to buy 79146.0 shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 1.83 million shares on Sep 16 ’24.
